RADIATION & RISK
Bulletin of the National Radiation and Epidemiological Registry
since 1992
About the Journal : 2018 : vol. 27, No. 4 : The radioprotective effects of nitric oxide synthase inhibitor T1023 on normal and malignant tissues

The radioprotective effects of nitric oxide synthase inhibitor T1023 on normal and malignant tissues

«Radiation and Risk», 2018, vol. 27, No. 4, pp.155-169

DOI: 10.21870/0131-3878-2018-27-4-155-169

Authors

Filimonova M.V. – Head of Lab., D. Sc., Biol. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249036. Tel.: +7 (484) 399-71-36; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Samsonova A.S. – Researcher.
Korneeva T.S. – Researcher.
Shevchenko L.I. – Lead. Researcher, C. Sc., Chem.
Saburov V.O. – Engineer.
Filimonov A.S. – Researcher.

A. Tsyb MRRC, Obninsk

Abstract

The aim of this research was to study ability of the new NOS inhibitor, N,Ssubstituted isothiourea (compound T1023), to effectively and selectively protect the normal somatic tissues from radiationinduced adverse effects. Methods of investigation included the study of T1023 influence on the development of skin acute radiation damage and antitumor effects of γradiation on intact mice and on the models of solid Ehrlich carcinoma (CE) for studying radiotherapyinduced effects; comparative estimation of the radioprotective efficacy and selectivity of T1023 and amifostine in normal tissues. The results of the experiments showed that T1023 at the optimal dose for prevention of ARS development (75 mg/kg), significantly reduced the radiationinduced alteration of the skin and underlying tissues, as well as the severity of acute radiation burns. DRF for acute radiationinduced skin reaction is 1.46. It is important to stress that no radioprotective effect of T1023 on the CE tissues, growing on the irradiated limb of animals was observed, the NOS inhibitor did not reduce the therapeutic effectiveness of radiation therapy. Amifostine (250 mg/kg) and T1023 (75 mg/kg), used in optimal radioprotective doses, were equally effective for selective protection of normal tissues. However, optimal dose of T1023 was twice as safe (26% LD16) than amifostine (50% LD16). T1023 manifests protective efficacy and selective protection of normal somatic tissues from radiationinduced damage at relatively safe doses. The protective properties of T1023 allow us to continue the study of this compound as the basis for development of an effective and safe pharmacological agent for the prevention of adverse effects of radiotherapy.

Key words
Ionizing radiation, radiation pharmacology, radioprotectors, radiation-induced damage, white autobred mice, cancer recurrence, experimental neoplasia, experimental radiotherapy, complications from radiotherapy, selective protection of health tissues, inhibitors of nitric oxide synthase.

References

1. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, V.G. Petrova. Moscow, P. Herzen MORI, 2017, 250 p. (In Russian).

2. Lushnikov E.F., Abrosimov A.Yu. Modern radiation pathology of a person: the problems of the methodology of research, etiology, pathogenesis and classification. Obninsk, MRRC, 2012. (In Russian).

3. Akleev A.V. Radiobiological regularities of the reaction of normal tissues during radiation therapy of tumors. Radiatsionnaya biologiya. Radioekologiya – Radiation Biology. Radioecology, 2014, vol. 54, no. 3, pp. 241-255. (In Russian).

4. Prasanna P.G., Stone H.B., Wong R.S., Capala J., Bernhard E.J., Vikram B., Coleman C.N. Normal tissue protection for improving radiotherapy: Where are the gaps? Transl. Cancer Res., 2012, vol. 1, no. 1, pp. 35-48.

5. Kim J.H., Jenrow K.A., Brown S.L. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. Radiat. Oncol. J., 2014, vol. 32, no. 3, pp. 103-115.

6. Filimonova M.V., Proskuryakov S.Ya., Shevchenko L.I., Shevchuk A.S., Lushnikova G.A., Makarchuk V.M., Arzamastsev E.V., Maltnovskaya K.I., Levitskaya E.L. Radioprotective properties of isothiourea derivatives with NO-inhibitory mechanism of action. Radiatsionnaya biologiya. Radioekologiya – Radiation Biology. Radioecology, 2012, vol. 52, no. 6, pp. 593-601. (In Russian).

7. Filimonova M.V., Shevchenko L.I., Trofimova T.P., Makarchuk V.M., Shevchuk A.S., Lushnikova G.A. On the mechanism of radioprotective effect of NO-synthase inhibitors. Radiatsionnaya biologiya. Radioekologiya – Radiation Biology. Radioecology, 2014, vol. 54, no. 5, pp. 500-506. (In Russian).

8. Filimonova M.V., Shevchenko L.I., Makarchuk V.M., Chesnakona E.A., Izmest’eva O.S., Korneeva T.S., Filimonov A.S. Radioprotective properties of NO-synthase inhibitor T1023: I. Indicators of radioprotective activity and interaction with other radioprotectors. Radiatsionnaya biologiya. Radioekologiya – Radiation Biology. Radioecology, 2015, vol. 55, no. 3, pp. 250-259. (In Russian).

9. Kuna P., Krajcovic C. Acute toxicity and radioprotective effectiveness of WR-2721 (Gammaphos) in rats. Cas. Lek. Cesk., 1981, vol. 120, no. 25, pp. 776-778.

10. Kuna P. Acute toxicity and radioprotective effectiveness of Gammaphos by intramuscularly administered to mice. Radiobiologiya – Radiobiology, 1985, vol. 25, no. 1, pp. 59-62. (In Russian).

11. Wells M., MacBride S. Radiation skin reactions. Supportive care in radiotherapy. Churchill Livingstone, 2003, pp. 135-159.

12. Makarchuk V.M., Filimonova M.V., Izmest’yeva O.S., Chesnakova E.A., Samsonova A.S., Korneeva T.S., Shevchenko L.I., Filimonov A.S. Radioprotective properties of NO-synthase inhibitor T1023: III. Mechanisms of radioprotective action in vivo. Radiatsionnaya biologiya. Radioekologiya – Radiation Biology. Radioecology, 2016, vol. 56, no. 6, pp. 590-597. (In Russian).

13. Le Q.T., Kim H.E., Schneider C.J. Muraközy G., Skladowski K., Reinisch S., Chen Y., Hickey M., Mo M., Chen M.G., Berger D., Lizambri R., Henke M. Palifermin reduced severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J. Clin. Oncol., 2011, vol. 29, no. 20, pp. 2808-2814.

14. Vasin M.V. Agents for the prevention and treatment of radiation damage. Moscow, 2006. 340 p. (In Russian).

15. Kouvaris J.R. Kouloulias V.E., Vlahos L.J. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist, 2007, vol. 12, no. 6, pp. 738-747.

16. Devine A., Marignol L. Potential of amifostine for chemotherapy and radiotherapy-associated toxicity reduction in advanced NSCLC: Meta-analysis. Anticancer Res., 2016, vol. 36, no. 1, pp. 5-12.

17. Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., Cohen G.I., Emami B., Gradishar W.J., Mitchell R.B., Thigpen J.T., Trotti A. 3rd, von Hoff D., Schuchter L.M. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol., 2009, vol. 27, no. 1, pp. 127-145.

18. Brunton L., Chabner B., Knollman B. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed. NY, McGraw Hill Professional, 2010, 1808 p.

19. Filimonova M.V., Ulyanenko S.E., Shevchenko L.I., Kuznetsova M.N., Makarchuk V.M., Chesnakova E.A., Samsonova A.S., Filimonov A.S. Radioprotective properties of NO-synthase inhibitor T1023: II. The ability for selective protection of normal tissue during radiotherapy of tumors. Radiatsionnaya biologiya. Radioekologiya – Radiation Biology. Radioecology, 2015, vol. 55, no. 3, pp. 260-266 (In Russian).

20. Filimonova M.V., Samsonova A.S., Korneeva T.S., Schevchenko L.I., Filimonov A.S. Study of the ability of a new nitric oxide synthase inhibitor INOS1 to selectively protect the normal tissue in the Ehrlich carcino-ma radiotherapy model. Radiatsiya i risk – Radiation and Risk, 2018, vol. 27, no. 2, pp. 37-45. (In Russian).

Full-text article (in Russian)